ClinicalTrials.Veeva

Menu

Two-Dose Methotrexate for Ectopic Pregnancy

University of Pennsylvania logo

University of Pennsylvania

Status and phase

Completed
Phase 3

Conditions

Ectopic Pregnancy

Treatments

Drug: Methotrexate

Study type

Interventional

Funder types

Other

Identifiers

NCT00194272
701460
RRU001

Details and patient eligibility

About

This study examines the safety and acceptability of a novel "two dose" regimen of methotrexate to treat ectopic pregnancy.

Full description

The regimen is an attempt to create a middle ground between the 2 commonly used regimens - "single dose" and "multi dose". The "multi dose" regimen is more effective, but the "single dose" regimen is more convenient for patients and has fewer side effects.

Enrollment

100 patients

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed diagnosis of ectopic pregnancy via

    • D&E without products of conception identified on frozen pathology or
    • VABRA without products of conception identified with pathologic evaluation or
    • Ultrasound visualization of a gestational sac in the adnexa, with definitive visualization of a yolk sac or fetal pole
  • the subject is hemodynamically stable without signs of hemoperitoneum

  • laparoscopy has not been performed

  • the subject is able to return for frequent follow-up care

  • normal renal and liver function have been documented within 2 days

  • normal white blood count and platelet count have been documented as per laboratory standard

  • normal chest x-ray was obtained if the subject has a history of pulmonary disease

  • no history of allergy or sensitivity to methotrexate or any component of its formulation

Exclusion criteria

  • breastfeeding
  • laboratory evidence of immunodeficiency
  • alcoholism or chronic liver disease
  • the concomitant use of non-steroidal anti-inflammatory drugs
  • blood dyscrasia such as leukopenia, thrombocytopenia, or severe anemia
  • active pulmonary disease
  • hepatic, renal, or hematological dysfunction
  • adnexal mass > or = 3.5 cm
  • presence of fetal cardiac motion
  • active major psychiatric disorder such as major depression, bipolar disease, psychotic disorder, or drug addiction
  • subjects unable or unwilling to comply with study procedures or illiterate

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems